These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1). Tsao R; Hurley EA Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112 [No Abstract] [Full Text] [Related]
25. "Obvious to try": a proper patentability standard in the pharmaceutical arts? Trask AV Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581 [No Abstract] [Full Text] [Related]
30. How would patent reform legislation in the United States impact the pharmaceutical industry? Williams AW Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953 [TBL] [Abstract][Full Text] [Related]
31. Patent drop reveals pressures on industry. Lawrence S Nat Biotechnol; 2004 Aug; 22(8):930-1. PubMed ID: 15286630 [No Abstract] [Full Text] [Related]
33. History of a gene patent: tracing the development and application of commercial BRCA testing. Williams-Jones B Health Law J; 2002; 10():123-46. PubMed ID: 14748275 [No Abstract] [Full Text] [Related]
35. Protecting rights to early-stage technology. Shuster MJ; Su H; Blaug S Nat Biotechnol; 2003 Jun; 21(6):701-3. PubMed ID: 12776151 [No Abstract] [Full Text] [Related]
36. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act. Genieser LH; McCann CE Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880 [TBL] [Abstract][Full Text] [Related]
37. US policy may encourage counterfeit drugs. Bouchie A Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826 [No Abstract] [Full Text] [Related]
38. Science and the law. Working through the patent problem. Walsh JP; Cohen WM; Arora A Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928 [No Abstract] [Full Text] [Related]